



Announcement Summary

---

**Entity name**

MEDIBIO LIMITED

**Date of this announcement**

Tuesday January 18, 2022

**The +securities the subject of this notification are:**

Other

**Total number of +securities to be issued/transferred**

<b>ASX +security code</b>	<b>Security description</b>	<b>Total number of +securities to be issued/transferred</b>	<b>Issue date</b>
MEBAD	OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	2,000,000	18/01/2022

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

MEDIBIO LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

**1.2 Registered number type**

ABN

**Registration number**

58008130336

**1.3 ASX issuer code**

MEB

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

18/1/2022



Part 2 - Issue details

---

**2.1 The +securities the subject of this notification are:**

Other

**Please specify**

Unlisted options granted to members of the Company's Growth & Advocacy Advisory Board as fees.

**2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:**

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

---

**Additional +securities in an existing class**

**ASX +security code and description**

MEBAD : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES

**Date the +securities the subject of this notification were issued**

18/1/2022

**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class**

Yes

**Any other information the entity wishes to provide about the +securities the subject of this notification**

Unlisted options granted to members of the Company's Growth & Advocacy Advisory Board (GAAB) as fees for participation in the GAAB.

**Please provide any further information needed to understand the circumstances in which you are notifying the issue of these +securities to ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B**

N/A



Issue details

---

**Number of +securities**

2,000,000

**Were the +securities issued for a cash consideration?**

No

**Please describe the consideration being provided for the +securities**

The securities are being issued as fees for services provided in relation to the GAAB.

**Purpose of the issue**

To pay for services rendered

**Additional Details**

The Option have an exercise price of \$0.01 (1 cent) per option and will expire on 1 October 2025.

---



## Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:  
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

**4.1 Quoted +Securities (Total number of each +class of +securities quoted)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
MEB : ORDINARY FULLY PAID	2,061,051,123
MEBOC : OPTION EXPIRING 28-FEB-2024	205,111,009
MEBN : ORDINARY FULLY PAID DEFERRED	687,018,109
MEBO : OPTION EXPIRING 28-FEB-2024 DEFERRED	343,509,055

**4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
MEBAN : OPTION EXPIRING 06-OCT-2023 EX \$0.012	10,210,500
MEBAD : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	52,137,113
MEBAO : OPTION EXPIRING 08-DEC-2025 EX \$0.011	11,250,000
MEBAE : OPTION EXPIRING 02-JUN-2022 EX 3C	27,500,000



Part 5 - Other Listing Rule requirements

---

**5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?**

No

**5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?**

No

**5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

Yes

**5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

2,000,000

**5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?**

N/A